Delano Ladd Sells 7,500 Shares of HealthEquity (NASDAQ:HQY) Stock

HealthEquity, Inc. (NASDAQ:HQYGet Free Report) EVP Delano Ladd sold 7,500 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $675,000.00. Following the sale, the executive vice president owned 91,141 shares in the company, valued at approximately $8,202,690. The trade was a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

HealthEquity Price Performance

HQY traded up $2.65 during trading on Monday, reaching $90.64. 1,399,147 shares of the stock were exchanged, compared to its average volume of 1,017,490. The business’s 50 day moving average price is $83.44 and its two-hundred day moving average price is $86.67. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.44 and a quick ratio of 3.44. The company has a market capitalization of $7.58 billion, a price-to-earnings ratio of 33.95, a P/E/G ratio of 1.60 and a beta of 0.21. HealthEquity, Inc. has a 1 year low of $72.76 and a 1 year high of $116.65.

HealthEquity (NASDAQ:HQYGet Free Report) last posted its earnings results on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. The company had revenue of $354.64 million for the quarter, compared to the consensus estimate of $352.02 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The firm’s revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, equities research analysts anticipate that HealthEquity, Inc. will post 3.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. cut their price target on HealthEquity from $129.00 to $123.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. BTIG Research cut their price target on HealthEquity from $130.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Barrington Research reissued an “outperform” rating and issued a $110.00 price target on shares of HealthEquity in a report on Friday, May 22nd. Royal Bank Of Canada boosted their price target on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Barclays cut their price target on HealthEquity from $118.00 to $110.00 and set an “overweight” rating for the company in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $111.53.

Check Out Our Latest Stock Report on HealthEquity

Hedge Funds Weigh In On HealthEquity

Institutional investors have recently added to or reduced their stakes in the business. Acumen Wealth Advisors LLC acquired a new position in HealthEquity in the fourth quarter valued at $27,000. Caitong International Asset Management Co. Ltd increased its stake in HealthEquity by 1,723.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $28,000 after purchasing an additional 293 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in HealthEquity in the fourth quarter valued at $28,000. Leonteq Securities AG increased its stake in HealthEquity by 159.9% in the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock valued at $32,000 after purchasing an additional 235 shares during the last quarter. Finally, Axiom Investment Management LLC acquired a new position in HealthEquity in the first quarter valued at $33,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Company Profile

(Get Free Report)

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.

Read More

Insider Buying and Selling by Quarter for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.